Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | LPO | P22079 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | SDHB | P21912 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29821821 | 1.00 | MAPT (0.47) | MAPTTP53LMNANPBWR1CMA1 | |
| SCHEMBL23168932 | 0.91 | NPBWR1 (0.43) | MAPTTP53LMNANPBWR1CMA1 | |
| SCHEMBL29821419 | 0.85 | MAPT (0.51) | MAPTTP53LMNANPBWR1CMA1 | |
| SCHEMBL23168654 | 0.85 | MAPT (0.51) | MAPTTP53LMNANPBWR1CMA1 | |
| SCHEMBL24819271 | 0.85 | NPBWR1 (0.48) | MAPTTP53LMNANPBWR1P2RX7 | |
| SCHEMBL29821988 | 0.85 | NPBWR1 (0.48) | MAPTTP53LMNANPBWR1P2RX7 | |
| SCHEMBL23168772 | 0.85 | MAPT (0.43) | MAPTTP53LMNANPBWR1P2RX7 | |
| SCHEMBL23168941 | 0.83 | THRB (0.38) | MAPTTP53LMNANPBWR1P2RX7 | |
| SCHEMBL23168950 | 0.83 | P2RX7 (0.40) | MAPTLMNAP2RX7KMT2A | |
| SCHEMBL29822173 | 0.83 | P2RX7 (0.40) | MAPTLMNAP2RX7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| WO-2021057791-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | MAPT 1873/4885TP53 2628/4885LMNA 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.